MONDAY, July 1, 2024 -- For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved...
Vous n'êtes pas connecté
Patients had numerically better but statistically similar five-year overall survival rates for IMRT (30.8 per cent) compared to 3D-CRT (26.6 per cent), as well as progression-free survival rates (16.5 per cent vs. 14.6 per cent). Taken together, these results favored IMRT, even though patients on the IMRT arm had significantly larger tumors and more tumors in unfavorable locations near the heart.
MONDAY, July 1, 2024 -- For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved...
An analysis of data from a randomised clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib,...
Pancreatic cancer patients who underwent chemotherapy both before and after surgery had longer survival rates compared to those who received...
Researchers have pinpointed a potential catalyst for aggressive lung cancer tumors among individuals residing in high-violence areas. Their study...
However, overall new electric car sales have decreased by 25 per cent for the first six months of this year
Researchers have discovered metabolic markers that forecast cancer patients' immunotherapy responses and survival outcomes, highlighting the...
TUESDAY, July 2, 2024 -- For patients with resectable pancreatic ductal adenocarcinoma (PDAC), the 12-month progression-free survival (PFS) may be...
Administering chemotherapy before surgery has shown benefits for select pancreatic cancer patients potentially improving treatment outcomes and...
Breast cancer is a complex disease with varying degrees of severity and treatment approaches. Central to understanding and managing breast cancer is...
FRIDAY, June 28, 2024 -- For patients with early-stage cervical cancer, disease-free and overall survival are lower for patients undergoing minimally...